Australian Doctor 1st September 2023 AD 1st Sept Issue | Page 8

8 NEWS
5 MINUTES * 1,2

8 NEWS

1 SEPTEMBER 2023 ausdoc . com . au

Can chores lower cancer risk ?

Carmel Sparke RUNNING for the bus , taking the stairs and vigorous domestic chores may help ward off cancer , with research showing a few minutes of incidental vigorous exercise a day can be oncoprotective .
The University of Sydney researchers say 3.5 minutes of intense cleaning and carrying groceries was linked to an 18 % lower incidence of cancer , compared to those people who did
not get their heart racing .
And just 4.5 minutes of such exercise — dubbed vigorous intermittent lifestyle physical activity ( VILPA ) — was tied to a 32 % reduction in risk of physical activity-related cancer .
The researchers stressed that while their results were observational , they pointed to a strong link between exercise and cancer incidence as shown in previous studies .
These included other
early-stage trials that showed intermittent vigorous physical activity led to rapid improvements in cardiorespiratory fitness , which could provide a biological explanation for the reduced cancer risk .
Other likely contributors included the role of physical activity in improving insulin sensitivity and chronic inflammation , they wrote .
Lead author Professor Emmanuel Stamatakis said it
was “ remarkable ” to see how upping the intensity of daily tasks in short bursts of around one minute had an effect .
“ VILPA was a bit like applying the principles of high-intensity interval training to your everyday life ,” he said .
The researchers used data from over 22,000 UK Biobank participants ( mean age 62 ) without cancer at baseline and who reported no structured exercise in their leisure time .
The patients wore wrist activity trackers for a week to measure the intensity , frequency and duration of VILPA .
They were followed up for seven years , during which 2356 new cancer events — including 1084 physical activity-related cancers — were reported .
“ The findings [ indicate ] small amounts of VILPA were associated with lower incident cancer risk ,” the authors said . JAMA Oncol 2023 ; 27 Jul .
Always read the label and follow the directions for use .
Treats moderate to severe hayfever symptoms .
References : 1 . Bousquet J et al . J Allergy Clin Immunol Prac 2018 ; 6 ( 5 ): 1726 – 1732 . ( Funded by MEDA Pharma GmbH & Co . KG ). 2 . Dymista ® Allergy Product Information . Dymista ® is a Viatris company trademark . Copyright © 2023 Viatris Inc . All rights reserved . DYM-2023-0365 . DH . DYM-003906-00 . Date Prepared : June 2023 .

CLEARS hayfever from

5 MINUTES * 1,2

* Rapid nasal symptom relief
Antihistamine
Dual-action

Corticosteroid strength

Now available without a script
2

PBAC to consider Wegovy

Rachel Carter NOVO Nordisk has applied for PBS funding for its subcutaneous weight loss drug Wegovy as a severe obesity treatment . The product contains semaglutide — the same active ingredient as Ozempic — and was approved by the TGA last year for adults with obesity , or overweight in the presence of at least one weight-related comorbidity .
The company ’ s PBAC application , which will be considered in November , requests a PBS listing “ for the treatment of severe obesity despite prior participation in an appropriate lifestyle-based weight management intervention ”.
In addition to the 2.4mg in 0.75mL pre-filled single-dose pen , the application also covers 0.25mg , 0.5mg and 1mg doses in 0.5mL pre-filled pens , as well as the 1.7mg in 0.75mL pre-filled pen .
The Novo Nordisk – funded STEP 1 study — published in The New England Journal of Medicine in early 2021 — found that 2.4mg of semaglutide once a week , in addition to lifestyle interventions , led to sustained and clinically relevant reductions in body weight .
The placebo-controlled trial included some 1900 adults with obesity or overweight .
The average reduction in body weight from baseline to week 68 of treatment was 14.9 % in those given semaglutide versus 2.4 % in the placebo group , and more patients in the semaglutide group achieved weight reductions of 5 %, 10 % and 15 % or higher .
However , participants who received semaglutide had higher rates of treatment discontinuation due to gastrointestinal events ( 4.5 % vs 0.8 % in the placebo group ).
The PBAC application comes amid ongoing supply disruptions of Ozempic , with the TGA warning in June that supply would likely remain “ unstable ” until the end of 2023 due to surging global demand . N Engl J Med 2021 ; 18 Mar .